Patritumab has been shown both to inhibit ligand-induced HER3 phosphorylation and to suppress the growth of pancreatic, non–small cell lung cancer, and colorectal cancer xenograft tumors [11, 12]. The gene discussed is ERBB3; the disease is colorectal cancer.